[Summary] Developing nucleic acid drugs based on RNA interference (RNAi) technol
Founded in 2007, Ribo Life Science focuses on the development of RNA interference (RNAi) technology and the industrialization of small nucleic acid drugs, and is one of the global pioneers in this field. The company has established an independently controllable small nucleic acid drug R&D platform with integrated full-technology-chain capabilities, built a globally integrated small nucleic acid drug development system, and created a rich siRNA drug pipeline through independent innovation, covering multiple diseases including cardiovascular, metabolic, kidney and liver diseases, especially in the field of chronic disease treatment.
With its international independent innovation R&D platform, the company has achieved full-life-cycle technology coverage of small nucleic acid drugs from early research to commercialization, including drug delivery, chemical modification, multi-target design, model-informed drug development, and pharmaceutical development and production. Among them, the company's independently developed liver-targeting RiboGalSTARTM delivery technology has advanced multiple products to Phase II clinical trials, with efficacy and safety well clinically validated. The company has reached a technology-platform-based cooperation with Germany's Boehringer Ingelheim, a highly representative collaboration among Chinese biotechnology companies, fully reflecting the high recognition of Ribo Life Science's R&D platform and scientific research strength by multinational pharmaceutical companies.
With a highly forward-looking global strategic layout, Ribo Life Science has established multiple R&D centers in Beijing and Suzhou, China, as well as in Europe. In the fierce global biopharmaceutical competitive landscape, driven by both a global R&D strategy and an international management team, the company has gathered an international team with extensive multinational pharmaceutical experience to support its sustainable development and global competitiveness, and to drive China's small nucleic acid pharmaceutical industry to the world's forefront.
What does Suzhou Ribo Life Science Co., Ltd. require? Who is Ribo Life Science hiring? Ribo Life Science recruitment: 生物/制药/化工/环保类占比最多占40.4%,其次是其他(研发和技术类)占27%. What education can get in at Ribo Life Science? 本科占比最多占57.3%,其次是硕士占31.5%. High education required at Ribo Life Science? 硕士占31.5%,博士占7.9%. Work experience required at Ribo Life Science? 5-10年占比最多占46.1%,其次是3-5年占25.8%. Where are the job locations at Ribo Life Science? 苏州占比最多占51.7%,其次是北京占43.8%. Based on job postings from the past year, for reference only.
Featuring 203 companies ,4 followers
Featuring 91 companies ,2 followers
Featuring 30 companies ,2 followers
Featuring 30 companies
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows